Conference Reports for NATAP

Back

IDSA Conference Infectious Disease Society Toronto, Oct 12-15, 2006     PL-100, a Next Generation Protease Inhibitor Against Drug-Resistant HIV: In Vitro and In Vivo Metabolism - (10/24/06)   Predictors of Response to TMC114 in POWER 1/2/3 - (10/17/06)   Pharmacokinetic interaction between TMC114 and ketoconazole, in the absence and presence of low-dose ritonavir - (10/17/06)   Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir - (10/17/06)   Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir, in the presence of low-dose ritonavir - (10/17/06)   TMC114/r tolerability in treatment-experienced, hepatitis B or C (HBV/HCV) co-infected patients in POWER 1 and 3 - (10/17/06)   Efficacy and Safety Results of Darunavir/ritonavir in Treatment-experienced Patients: POWER 3 - (10/17/06)   Safety/Lipids & Durability of Viral Load Suppression of TMC114 in POWER 1/2 Week 48 - (10/17/06)   Higher Rectal HIV RNA Levels in Men who have Sex with Men (MSM) with Concurrent Rectal HSV Shedding - (10/17/06)